BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 24686195)

  • 1. Evaluating heterogeneity of primary tumor (18)F-FDG uptake in breast cancer with a dedicated breast PET (MAMMI): a feasibility study based on correlation with PET/CT.
    Koolen BB; Vidal-Sicart S; Benlloch Baviera JM; Valdés Olmos RA
    Nucl Med Commun; 2014 May; 35(5):446-52. PubMed ID: 24686195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First clinical experience with a dedicated PET for hanging breast molecular imaging.
    Koolen BB; Aukema TS; González Martínez AJ; Vogel WV; Caballero Ontanaya L; Vrancken Peeters MJ; Vroonland CJ; Rutgers EJ; Benlloch Baviera JM; Valdés Olmos RA
    Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):92-100. PubMed ID: 23474637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a Hanging-Breast PET System for Primary Tumor Visualization in Patients With Stage I-III Breast Cancer: Comparison With Standard PET/CT.
    Teixeira SC; Rebolleda JF; Koolen BB; Wesseling J; Jurado RS; Stokkel MP; Del Puig Cózar Santiago M; van der Noort V; Rutgers EJ; Valdés Olmos RA
    AJR Am J Roentgenol; 2016 Jun; 206(6):1307-14. PubMed ID: 27058014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.
    Williams JM; Rani SD; Li X; Arlinghaus LR; Lee TC; MacDonald LR; Partridge SC; Kang H; Whisenant JG; Abramson RG; Linden HM; Kinahan PE; Yankeelov TE
    Med Phys; 2015 Jul; 42(7):3801-13. PubMed ID: 26133582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of ¹⁸F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma.
    Pant V; Sen IB; Soin AS
    Nucl Med Commun; 2013 Aug; 34(8):749-57. PubMed ID: 23689586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral heterogeneity of F-18 FDG uptake differentiates between gastrointestinal stromal tumors and abdominal malignant lymphomas on PET/CT.
    Watabe T; Tatsumi M; Watabe H; Isohashi K; Kato H; Yanagawa M; Shimosegawa E; Hatazawa J
    Ann Nucl Med; 2012 Apr; 26(3):222-7. PubMed ID: 22187313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of MRI Indeterminate Breast Lesions Using Dedicated Breast PET and Prone FDG PET-CT in Patients with Breast Cancer-A Proof-of-Concept Study.
    Malhotra A; Tincey S; Naidu V; Papagiorcopulo C; Ghosh D; Tan PH; Wickham F; Wagner T
    J Pers Med; 2020 Sep; 10(4):. PubMed ID: 32992995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
    Zhang X; Wu F; Han P
    Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors.
    Cochet A; Pigeonnat S; Khoury B; Vrigneaud JM; Touzery C; Berriolo-Riedinger A; Dygai-Cochet I; Toubeau M; Humbert O; Coudert B; Fumoleau P; Arnould L; Brunotte F
    J Nucl Med; 2012 Apr; 53(4):512-20. PubMed ID: 22343501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the pretreatment tumor sampling location correspond with metabolic activity on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy?
    Koolen BB; Elshof LE; Loo CE; Wesseling J; Vrancken Peeters MJ; Vogel WV; Rutgers EJ; Valdés Olmos RA
    Eur J Radiol; 2013 Dec; 82(12):2353-8. PubMed ID: 23998705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
    Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
    J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?
    Yang Z; Sun Y; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
    Clin Breast Cancer; 2013 Oct; 13(5):359-63. PubMed ID: 23787040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of F-18 fluorodeoxyglucose posıtron emıssıon tomography/computed ın carcınoma of unknown primary.
    Elboga U; Kervancioğlu S; Sahin E; Basibuyuk M; Celen YZ; Aktolun C
    Int J Clin Exp Pathol; 2014; 7(12):8941-6. PubMed ID: 25674269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.
    Song BI; Lee SW; Jeong SY; Chae YS; Lee WK; Ahn BC; Lee J
    J Nucl Med; 2012 Sep; 53(9):1337-44. PubMed ID: 22870824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of brown adipose tissue activation in 18F-FDG PET/CT of breast cancer patients receiving neoadjuvant systemic therapy.
    Aukema TS; Vogel WV; Hoefnagel CA; Valdés Olmos RA
    J Nucl Med Technol; 2010 Mar; 38(1):24-7. PubMed ID: 20159933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semiquantitative Analysis of the Biodistribution of the Combined ¹⁸F-NaF and ¹⁸F-FDG Administration for PET/CT Imaging.
    Minamimoto R; Mosci C; Jamali M; Barkhodari A; Habte F; Jackson T; Mittra E; Gambhir SS; Iagaru A
    J Nucl Med; 2015 May; 56(5):688-94. PubMed ID: 25840978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
    Li DL; Xu YK; Wang QS; Wu HB; Li HS
    Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More accurate than MRI measurement of tumor size in breast cancer by using the peri-tumoral halo uptake layer method of the
    Park SH; Seo M; Choi HJ; Bae K; Bang M; Jun S
    Hell J Nucl Med; 2018; 21(2):108-114. PubMed ID: 30006644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-avid sclerotic bone metastases in breast cancer patients: a PET/CT case series.
    Koolen BB; Vegt E; Rutgers EJ; Vogel WV; Stokkel MP; Hoefnagel CA; Fioole-Bruining A; Vrancken Peeters MJ; Valdés Olmos RA
    Ann Nucl Med; 2012 Jan; 26(1):86-91. PubMed ID: 21953212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.